Approach

Summary

Licensing status

Publication and contact information

Drug platforms

Influenza A virus hemagglutinin stem fragment to induce broadly neutralizing antibodies

In vitro and mouse studies suggest the influenza A virus hemagglutinin stem fragment could help protect against influenza virus infection. The fragment contained an isoleucine zipper that produced H1HA10-Foldon, a trimeric hemagglutinin stem immunogen that harbors about 95% of the epitope bound by the broadly neutralizing antibody CR6261. In binding assays, sera obtained from mice immunized with H1HA10-Foldon neutralized five different strains of influenza virus, whereas sera from mice immunized with an inactivated virus did not. In mice, prophylactic immunization with H1HA10-Foldon protected against lethal challenge with influenza virus. Next steps include testing the immunogen with other adjuvants and immunization regimes in mice and ferrets.
Johnson & Johnson's Crucell N.V. unit has the hemagglutinin-targeting, broadly neutralizing antibody CR6261 in Phase I trials to treat influenza.

SciBX 7(27); doi:10.1038/scibx.2014.811
Published online July 17, 2014

Patent application filed; available for licensing from the Indian Institute of Science

Mallajosyula, V.V.A. et al. Proc. Natl. Acad. Sci. USA; published online
 June 9, 2014;
doi:10.1073/pnas.1402766111
Contact: Raghavan Varadarajan, Indian Institute of Science, Bangalore, India
e-mail:
varadar@mbu.iisc.ernet.in
Contact: Xiaoping Liang, Merck Research Laboratories, West Point, Pa.
e-mail:
liangxiaoping@walvax.com